Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 4

Comparative analysis of peripheral Th1, Treg, and DCs between healthy controls and CHB patients .

	Healthy controls	Treatment-naïve patients	Patients with partial response to ETV
CD4^+ T cell of PBMCs (%)	60.30 (56.50–64.60)	16.20 (7.30–56.40)	49.30^,△ (46.00–63.30)
Th1 of CD4^+ T cells (%)	60.40 (58.80–62.2)	10.50 (8.70–14.1)	10.00 (3.10–14.20)
Treg of CD4^+ T cells (%)	4.00 (3.09–5.18)	12.68 (4.98–41.48)	2.88^△△ (0.50–8.32)
DCs of PBMCs (%)	0.29 (0.27–0.40)	0.07 (0.01–0.13)	0.15^,△△ (0.10–0.22)
PD-1 on Th1 (MFI)	437.5 (412.8–452.8)	523.1 (423.2–639.4)	594.5^,△△ (553.0–696.4)
PD-1 on Treg (MFI)	1118.2 (856.8–2628.9)	7164.1 (3022.4–25690.6)	5677.8 (1372.3–11151.0)
PD-L1 on DCs (MFI)	2010.30 (1683.5–2852.5)	3432.1 (2080.6–6800.3)	2530.3 (1764.3–4098.9)

Notes: , compared with healthy controls; , compared with healthy controls; ^△, compared with treatment-naïve patients; ^△△, compared with treatment-naïve patients.